指南与共识胸部技术与安全CT

中华医学会肿瘤学分会肺癌临床诊疗指南(2026版)

[Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2026 edition)].
指南 / 共识 · Zhonghua Zhong Liu Za Zhi · 2026-01-01

本指南由中华医学会肿瘤学分会组织多学科专家经共识会议制定,用于规范中国肺癌防治并提升诊疗水平。2026版在肺癌筛查、分子病理检测及非小细胞肺癌治疗推荐方面较2025版均有更新,涵盖筛查、诊断、病理、基因检测、治疗与随访。指南以NMPA批准适应证为核心原则,结合国际指南与中国临床实践现状提供循证建议。

要点

  • 低剂量螺旋CT筛查部分细化了质量控制要求,并新增机会性筛查及人工智能技术应用介绍和适用范围。
  • 分子病理检测新增多个基因检测相关建议,并更新EGFR、ALK、KRAS G12C、HER-2、MET等分子亚型治疗推荐。
  • 不可切除Ⅲ期非小细胞肺癌同步或序贯放化疗后的免疫巩固治疗选择有所补充,阅片报告中应关注分期信息。

核心结论

  • 2026版指南以NMPA批准适应证为核心,结合国际推荐与中国实践,整合肺癌筛查至随访的最新循证医学证据,为临床及影像等专业人员提供推荐建议。

研究设计与样本

  • 由中华医学会肿瘤学分会组织呼吸内科、肿瘤内科、胸外科、放疗科、影像科和病理科专家,经共识会议制定。
  • 指南制定以NMPA批准适应证为核心原则,以中国实际可应用的药品为基础,结合国际指南推荐意见和中国临床实践现状。

诊断标准与关键数值

  • 肺癌筛查部分细化了低剂量螺旋CT筛查的质量控制要求,并增加了机会性筛查及人工智能技术应用的介绍和适用范围。
  • 分子病理检测内容结合最新临床研究结果及NMPA新批准适应证进行了补充,新增多个基因检测相关建议。
  • 围术期非小细胞肺癌新辅助及辅助治疗方案根据新获批药物和适应证进行了更新。
  • 不可切除Ⅲ期非小细胞肺癌同步或序贯放化疗后的免疫巩固治疗选择有所补充。

临床应用与阅片要点

  • 影像科专业人员可参考本指南了解肺癌筛查中低剂量螺旋CT质控、机会性筛查及人工智能辅助应用的适用范围。
  • 报告中与分期相关的信息,如不可切除Ⅲ期非小细胞肺癌状态,可能影响后续放化疗后免疫巩固治疗决策。
  • 分子病理检测建议更新后,影像科与临床沟通时应关注EGFR、ALK、KRAS G12C、HER-2及MET等分子亚型检测状态对治疗路径的影响。

局限性

  • 本指南以NMPA批准适应证为核心原则,并以中国实际可应用的药品为基础,推荐范围受中国药品可及性影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

To further standardize the prevention and management of lung cancer in China, improve the level of diagnosis and treatment, enhance patient prognosis, and provide evidence-based professional recommendations for clinical practitioners at all levels, the Oncology Society of Chinese Medical Association organized experts from respiratory medicine, medical oncology, thoracic surgery, radiation oncology, radiology, and pathology to develop the "Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2026 edition)" through a consensus conference. Compared with the 2025 edition, the 2026 edition incorporates updates and refinements in several aspects. In the lung cancer screening section, quality control requirements for low-dose computed tomography screening have been further detailed, and the introduction and scope of application of opportunistic screening and artificial intelligence technologies in lung cancer screening have been added. In the pathology section, on the basis of the latest clinical research findings and newly approved indications by the National Medical Products Administration (NMPA), the recommendations for molecular pathological testing have been supplemented, with several new gene testing-related recommendations added. In the treatment section, perioperative neoadjuvant and adjuvant treatment regimens for non-small cell lung cancer have been updated according to newly approved drugs and indications; additional options for consolidation immunotherapy after concurrent or sequential chemoradiotherapy for unresectable stage Ⅲ non-small cell lung cancer have been incorporated; and first-line and subsequent-line treatment strategies for patients with advanced epidermal growth factor receptor (EGFR)-mutations have been further refined. In addition, treatment recommendations for patients with non-small cell lung cancer harboring molecular subtypes such as anaplastic lymphoma kinase (ALK) fusion, KRAS G12C mutation, human epidermal growth factor receptor 2 (HER-2) mutations, and MET amplification have also been updated based on the approval of novel agents. This guideline adheres to NMPA-approved indications as the core principle, is grounded in drugs practically available in China and integrates recommendations from international guidelines as well as the current status of clinical practice in China. It synthesizes the latest evidence-based medical advances in recent years covering lung cancer screening, diagnosis, pathology, genetic testing, immunologic and molecular biomarker testing, treatment modalities, and follow-up, with the aim of providing reasonable and practical recommendations for clinicians at all levels, as well as professionals in radiology, laboratory medicine, and related disciplines.

为进一步规范中国肺癌的防治措施、提高肺癌的诊疗水平、改善患者的预后、为各级临床医务人员提供专业的循证医学建议,中华医学会肿瘤学分会组织呼吸内科、肿瘤内科、胸外科、放疗科、影像科和病理科专家,经过共识会议制订了《中华医学会肿瘤学分会肺癌临床诊疗指南(2026版)》。与2025版指南相比,2026版指南在多个方面进行了更新和完善。肺癌筛查部分进一步细化了低剂量螺旋CT筛查的质量控制要求,并增加了机会性筛查及人工智能技术在肺癌筛查中的应用介绍和适用范围。病理诊断部分结合最新临床研究结果及中国国家药品监督管理局(NMPA)新批准适应证,对分子病理检测内容进行了补充,新增了多个基因检测相关建议。治疗部分根据新获批的药物和适应证,对围术期非小细胞肺癌的新辅助及辅助治疗方案进行了更新;对不可切除Ⅲ期非小细胞肺癌同步或序贯放化疗后的免疫巩固治疗选择进行了补充;对晚期表皮生长因子受体(EGFR)基因突变患者一线及后线治疗策略进行了完善。此外,针对间变性淋巴瘤激酶(ALK)融合、KRAS G12C突变、人表皮生长因子受体2(HER-2)基因突变及MET扩增等分子亚型的非小细胞肺癌患者,也根据新型药物获批情况更新了相应治疗推荐。本指南以NMPA批准适应证为核心原则,以中国实际可应用的药品为基础,结合国际指南推荐意见和中国临床实践现状,整合近年来肺癌筛查、诊断、病理、基因检测、免疫分子标志物检测和治疗手段以及随访等诊治方面的最新循证医学证据,旨在为各级临床医师、影像、检验等专业人员提供合理的推荐建议。.

来源:Zhonghua Zhong Liu Za Zhi,查看原文。版权归原作者所有。

引用

  1. [Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2026 edition)]. Zhonghua Zhong Liu Za Zhi. 2026. PMID: 42764215. doi:10.3760/cma.j.cn112152-20260511-00228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。